138 related articles for article (PubMed ID: 38213041)
21. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
23. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.
LaPensee EW; Schwemberger SJ; LaPensee CR; Bahassi el M; Afton SE; Ben-Jonathan N
Carcinogenesis; 2009 Aug; 30(8):1298-304. PubMed ID: 19443905
[TBL] [Abstract][Full Text] [Related]
24. Nasal spray administration of bromocriptine: pharmacology and effect on serum prolactin level in puerperal women.
Cicinelli E; Cignarelli M; Petruzzi D; Matteo G; Ruccia C; Schonauer LM
Gynecol Endocrinol; 1996 Dec; 10(6):391-6. PubMed ID: 9032565
[TBL] [Abstract][Full Text] [Related]
25. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
[TBL] [Abstract][Full Text] [Related]
26. Discordant responses of prolactinoma to two different dopamine agonists.
Ahmed SR; Shalet SM
Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834
[TBL] [Abstract][Full Text] [Related]
27. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy.
LaPensee EW; Ben-Jonathan N
Endocr Relat Cancer; 2010 Jun; 17(2):R91-107. PubMed ID: 20071456
[TBL] [Abstract][Full Text] [Related]
28. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
30. Prolactin secretion and menstrual function after long-term bromocriptine treatment.
Rasmussen C; Bergh T; Wide L
Fertil Steril; 1987 Oct; 48(4):550-4. PubMed ID: 3653413
[TBL] [Abstract][Full Text] [Related]
31. Failure of bromocriptine therapy to control juvenile mammary hypertrophy.
Arscott GD; Craig HR; Gabay L
Br J Plast Surg; 2001 Dec; 54(8):720-3. PubMed ID: 11728119
[TBL] [Abstract][Full Text] [Related]
32. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.
Munro AF; Cameron DA; Bartlett JM
Oncogene; 2010 Sep; 29(38):5231-40. PubMed ID: 20676126
[TBL] [Abstract][Full Text] [Related]
33. Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer.
Norimura S; Kontani K; Kubo T; Hashimoto SI; Murazawa C; Kenzaki K; Liu D; Tamaki M; Aki F; Miura K; Yoshizawa K; Tangoku A; Yokomise H
J Cancer Res Ther; 2018; 14(2):409-415. PubMed ID: 29516929
[TBL] [Abstract][Full Text] [Related]
34. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
36. Failure of dopamine and bromocriptine to affect prolactin release and cell growth in the dopamine receptor-deficient 235-1 clone.
Cronin MJ; Perkins SN; Keefer DA; MacLeod RM
Mol Cell Endocrinol; 1982 Oct; 28(2):229-46. PubMed ID: 7128925
[TBL] [Abstract][Full Text] [Related]
37. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
Shao F; Pang X; Baeg GH
Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
[TBL] [Abstract][Full Text] [Related]
38. One minute of bromocriptine irreversibly inhibits prolactin release for hours.
Cronin MJ; Evans WS; Thorner MO
Eur J Pharmacol; 1984 Mar; 99(1):85-90. PubMed ID: 6723793
[TBL] [Abstract][Full Text] [Related]
39. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
40. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
Leehy KA; Truong TH; Mauro LJ; Lange CA
J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
